Meet Our Immunology Leadership Team
DAVID M. LEE, M.D., Ph.D.
GLOBAL THERAPEUTIC AREA HEAD
David M. Lee, M.D., Ph.D., is Global Immunology Therapeutic Area Head for the Janssen Pharmaceutical Companies of Johnson & Johnson where he leads a team focused on end-to-end pipeline and a portfolio of treatments for immune-mediated disease. Under his leadership, Immunology researchers are working to build on the success of our current portfolio, which includes STELARA® (ustekinumab) and TREMFYA® (guselkumab).
Prior to joining Johnson & Johnson in September 2018, David was based in Basel, Switzerland, where he served as Global Head, Immunology, Inflammation and Infectious Disease Discovery and Translation Area for Roche, and prior to that, as Global Head of Autoimmunity, Dermatology, and Transplant Translational Medicine at the Novartis Institutes for BioMedical Research. In each of these roles, he led on the strategic approaches that fed the companies’ pipelines, prioritized assets, and accelerated their development. His ability to develop external collaborations and lead and develop his teams, was central to his success in each organization.
Before transitioning to the pharmaceutical industry, David was a faculty member at Brigham and Women’s Hospital/Harvard Medical School. While there, his research laboratory focused on disease mechanisms in rheumatology and he was also a practicing rheumatologist. As a precursor to his career in industry, while at Harvard, he also participated in co-founding multiple start-ups. Ultimately, one – a biotech – was acquired by a major pharmaceutical company.
He is an active author and speaker, and has completed more than 80 peer-reviewed publications, book chapters, and more than 100 lectures/seminars.
David earned his undergraduate degree at Stanford University, where he discovered his fascination with the intricacies of the immune system. He subsequently earned his M.D. and Ph.D. in Microbiology/Immunology from the Duke University School of Medicine. His passion for developing new medicines is rooted in his experiences treating patients as a practicing rheumatologist.
Follow David on LinkedIn here.
David M. Lee, M.D., Ph.D.
Global Therapeutic Area Head
WORLDWIDE VICE PRESIDENT
Candice Long is the Worldwide Vice President for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. Together with the Immunology Research & Development Therapeutic Area leader, she has end-to-end responsibility for the Janssen Immunology portfolio and pipeline, leading global commercial efforts to build and maximize value in areas of high unmet need.
In her former role as U.S. President, Infectious Diseases & Vaccines (ID&V), Candice was responsible for steering the ID&V business to deliver on near- and long-term growth objectives to advance Janssen’s HIV portfolio, strengthening organizational readiness to introduce vaccines, and leading ongoing efforts to expand the breadth of the business.
Prior to that role, Candice was Vice President of Marketing for U.S. Immunology. During her time with Immunology, business grew significantly with the successful launch of TREMFYA® (guselkumab) for psoriasis and STELARA® (ustekinumab) for ulcerative colitis, with increased focus on fulfillment through new support services while effectively protecting patients’ ability to maintain success on their STELARA and REMICADE® (infliximab) treatments. Candice began her career at Johnson & Johnson and has held various other roles with increasing responsibilities in the Pharmaceuticals and Consumer sectors.
Passionate about digital innovation and advocacy in healthcare, Candice has also served as the Executive Sponsor of Janssen Cares, the Company’s comprehensive employee giving program. In addition, she served as an Executive Sponsor of the Company’s Employee Resource Group, Open&Out, a global network of LGBTQ+ and Ally individuals who seek to make a difference by creating safe and inclusive workspaces, fostering healthier communities, and empowering employees.
She earned an MBA from the College of William & Mary in Williamsburg, Virginia, and received a Bachelor of Science in Business Administration and Bachelor of Arts in History from Mary Washington College in Fredericksburg, Virginia.
Follow Candice on LinkedIn here.
Worldwide Vice President
KATIE ABOUZAHR, M.D.
AUTOANTIBODY PORTFOLIO AND MATERNAL FETAL DISEASE AREA LEADER
Katie Abouzahr, M.D., is Vice President, Autoantibody (AAb) Portfolio and Maternal Fetal Disease Area Leader at Janssen Research and Development (R&D), LLC. In this role, Katie leads the development of assets in the AAb pathway portfolio and maternal fetal immunology disease area, of which includes Janssen’s lead investigative asset, nipocalimab, to address auto and alloantibody-driven diseases in multiple indications across maternal fetal, rare autoantibody, and prevalent rheumatology.
Katie joined Janssen in 2019 as a member of the Global Janssen R&D Strategy and Operations group and served as Vice President, Compound Development Team Leader (CDTL) for STELARA® (ustekinumab), Janssen’s largest commercialized product, overseeing its development in multiple indications and its lifecycle management strategy.
Prior to her work at Janssen, Katie served as a Principal at the Boston Consulting Group in London and Philadelphia for 12 years, where she worked on a range of engagements across the healthcare sector in the UK and US. Prior to that, she practiced as a Medical Doctor for the National Health Service (NHS) in London.
Katie received her Bachelor of Science in Chemical Pathology at Imperial College in London, and her Bachelor of Medicine, Bachelor of Surgery (MBBS) at Imperial College School of Medicine. She earned her Membership of the Royal College of Physicians of the UK in 2006.
Follow Katie on LinkedIn here.
Katie Abouzahr, M.D.
Autoantibody Portfolio and Maternal Fetal Disease Area Leader
CYNTHIA ACCUOSTI JONES
COMMERCIAL AUTOANTIBODY AND MATERNAL FETAL DISEASE AREA LEADER
Cynthia Accuosti Jones is Vice President, Commercial Autoantibody and Maternal Fetal Disease Area Leader at Janssen Global Services. In this role, she is responsible for developing and executing the global commercial strategy to support the discovery, development, and launch of new therapies to address auto and alloantibody-driven diseases, with a focus on maximizing the value and patient impact of therapeutic assets across indications spanning from maternal fetal, rare autoantibody, and prevalent rheumatology.
Prior to her current role, Cynthia served as the Director of Marketing for the Prostate Portfolio within Janssen Oncology, responsible for ERLEADA® (apalutamide) and the launch readiness planning for the niraparib/abiraterone dual-action tablet. Prior to this role, she held multiple positions within the Janssen Oncology marketing team, and since joining Janssen in 2004, has demonstrated a track record of success across Marketing, Account Management, Pricing Strategy, and Finance.
Cynthia holds a B.S. dual degree in Finance & International Business from Georgetown University, and a master’s certificate in Health Policy from Thomas Jefferson University. She is also a Tribute to Women and Industry (TWIN) recipient, and was named a Healthcare Women’s Business Association Rising Star in 2015.
Follow Cynthia on LinkedIn here
Cynthia Accuosti Jones
Commercial Autoantibody and Maternal Fetal Disease Area Leader
DISEASE AREA COMMERCIAL LEADER
Richard Appiah is Vice President, Disease Area Commercial Leader, Gastroenterology for the Immunology Therapeutic Area at Janssen Global Services. In this role, he is responsible for leading the commercial strategy to support the discovery, development, and launch of new therapeutics within the inflammatory bowel disease area.
Prior to this role, Richard served as Senior Director, Franchise Strategy Marketing for the U.S. Cardiovascular & Metabolism organization at Janssen, significantly contributing to growth of the XARELTO® (rivaroxaban) brand. Under his leadership, XARELTO established a first-of-its-kind, direct-to-patient commercial model designed to improve adherence and lower patients’ out-of-pocket cost. Richard joined Johnson & Johnson in 2002 and has held roles of increasing responsibility at Janssen in Oncology, Neuroscience, and Immunology.
Beyond his work at Johnson & Johnson, Richard spent four years at Pfizer in the specialty business unit where he was responsible for payer marketing and contracting strategies for a portfolio of biologic products.
Richard holds Bachelor and M.S. degrees from Syracuse University and an MBA from Harvard Business School.
Follow Richard on LinkedIn here.
Disease Area Commercial Leader
Paul Duncan is Senior Director, External Innovation for the Immunology Global Commercial Strategy Organization of Janssen Global Services. In this role, Paul is responsible for leading the overall external innovation strategy and operations for Janssen Immunology, partnering closely with the Immunology Research & Development and New Business Development teams.
During his tenure with Johnson & Johnson, Paul has made significant contributions across a number of therapeutic areas and brings extensive commercial experience to his role. Prior to his current role, Paul served as the National Sales Director, Rheumatology, where under his leadership, the rheumatology franchise successfully launched SIMPONI ARIA® (golimumab) and STELARA® (ustekinumab), while navigating the challenges of managing a portfolio and accelerating the performance of growth assets in a complex access environment. Paul played a key role in the advancement of the Janssen customer engagement model, integrating real world evidence, quality, and outcomes-based data. In addition, he led the harmonization of the Janssen sales competency model and contributed to the evolution of the strategic talent approach across Janssen North America.
Prior to his leadership in Sales, Paul was a Group Product Director supporting the rheumatology franchise where he led the professional marketing effort. During his tenure, SIMPONI® (golimumab) experienced market leading growth in the anti-TNF category. Additionally, he was Regional Marketing Leader, Asia Pacific within the anti-infective and urology franchises, where he led the successful launch of DORIBAX® (doripenem) in eight countries and PRILIGY (dapoxetine) in two countries. Paul has held positions of increasing responsibility in marketing and has a long track record of success as a sales leader with previous experience as both a District Manager and Region Business Director for Janssen.
Paul earned a B.A. in Chemistry and a B.S. in Biochemistry from North Carolina State University and an MBA from Virginia Commonwealth University in Richmond, Virginia.
Follow Paul on LinkedIn here.
GLOBAL THERAPEUTIC AREA MARKET ACCESS LEADER
Jochen Fleischmann is the Vice President, Global Therapeutic Area Market Access Leader, Immunology, for the Janssen Pharmaceutical Companies of Johnson & Johnson. Together with his team, he oversees the creation and implementation of the Immunology global market access strategies for all compounds in the Immunology portfolio. He jointly leads integrated evidence generation with Medical Affairs team members. In partnership with the Global Commercial Strategy Organization (GCSO) Market Access hub, Research & Development, regional partners, and external stakeholders, he drives product value and shapes the payer environment and healthcare policies.
Before joining the Immunology team, he was the Global Therapeutic Area Market Access Leader for Neuroscience. In that role, Jochen was instrumental in shaping, adapting, and implementing the Market Access strategies for SPRAVATO® (esketamine) and PONVORY® (ponesimod), leading the respective teams through challenging payer environments and strongly contributing to driving forward critical initiatives. Together with his team, he has created the foundation for future Market Access success of Janssen’s Neuroscience pipeline.
Jochen began his career with Johnson & Johnson in 2006 at Janssen Germany and subsequently held several positions within Market Access and Governmental Affairs with growing responsibilities. As the Director Market Access, Health Economics and Outcomes Research in Janssen Germany from 2011 to 2015, Jochen successfully prepared the Company for the newly established AMNOG reimbursement process, leading the team through more than 10 business critical submissions, contributing substantially to establishing Janssen as the industry leading market access company in the key German market. Jochen’s experiences were enriched through cross-functional experiences in policy focused and commercial roles such as the EMEA Hematology Integrated Brand Value Team Leader, where he successfully grew the Acute Myeloid Leukemia business and prepared future assets for launch.
Jochen holds a doctoral degree in Economics and received his education in Economics and Health Economics from the University of Bayreuth, Germany, and Massey University, New Zealand.
Follow Jochen on LinkedIn here.
Global Therapeutic Area Market Access Leader
DAVID GORDON, M.B., CH.B.
Global Head of Clinical Development
David Gordon, M.B., Ch.B., is Global Head of Clinical Development for the Immunology Therapeutic Area (TA) at Janssen Research & Development, LLC. In this role, he is responsible for implementing and execution of the Development portfolio for Immunology. He will advance the Immunology strategy to develop new and different mechanisms and treatment modalities to help patients achieve immune homeostasis, and ultimately remission from symptoms, across a breadth of immune-mediated diseases.
Prior to his role at Janssen, David served as Chief Medical Officer at Aclaris Therapeutics. Before that, he spent more than 18 years with GlaxoSmithKline where he held a variety of roles, including Clinical Vice President and Medicine Development Leader for their immuno-inflammation and biopharmaceutical groups, and Senior Vice President and Head of Dermatology Research and Development.
David received his medical degree and Bachelor of Medical Biology from the University of Aberdeen in Aberdeen, U.K., and a Diploma in Anaesthetics from the Faculty of The Royal College of Anaesthetists in London. He is accredited as a specialist in pharmaceutical medicine by the Faculty of Pharmaceutical Medicine in London and is a Fellow of the Faculty.
Follow David on LinkedIn here.
David Gordon, M.B., Ch.B.
Global Head of Clinical Development
Global Therapeutic Area Leader
Dermatology & Rheumatology
Tom Mickelson is Vice President, Dermatology & Rheumatology Global Therapeutic Area Leader at Janssen Research & Development, LLC. In this role, he leads the global commercial strategy for Janssen’s Dermatology and Rheumatology portfolio and pipeline and creates the short and long-term end to end disease area strategy in close collaboration with functional and global counterparts. He continues to drive commercialized portfolio growth and differentiation while preparing for the launch of future assets and works in close partnership with Research & Development and Business Development to identify future opportunities to transform outcomes for patients and maximize Janssen’s portfolio in strategic and innovative ways.
In his prior role at Janssen as Director of Marketing for U.S. Dermatology, Tom drove new and innovative strategies coupled with disciplined execution to accelerate the competitiveness of TREMFYA® today and into the future.
Prior to his time with Johnson & Johnson, Tom had an extensive career with Eli Lilly and Company where he held a number of leadership positions across the organization, both in the U.S. and abroad. He began his career with several cross-functional roles across numerous therapeutic areas including sales management, thought leader liaison, strategy and operations, six sigma, and marketing. He then moved outside of the U.S. where he led the Lilly and Boehringer Ingelheim alliance team based in Germany as the Global Brand Director for JARDIANCE® (empagliflozin).
He was then named Chief Marketing Officer for the China affiliate, where he led the transformational efforts in marketing and commercial capabilities. In his transition back to the U.S., he became the Head of Tanezumab and the Lilly-Pfizer alliance team where he led the commercialization and launch efforts for the U.S. affiliate. Tom then worked as the U.S. marketing leader for TALTZ® (ixekizumab).
Tom has his undergraduate degree from Bradley University and an MBA from Northwestern Kellogg School of Management.
Follow Tom on LinkedIn here.
Global Therapeutic Area Leader
Dermatology & Rheumatology
LLOYD S. MILLER, M.D., PH.D.
IMMUNODERMATOLOGY DISEASE AREA LEADER
Lloyd S. Miller, M.D., Ph.D., is Vice President, Immunodermatology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Lloyd drives the development and implementation of the scientific strategy for immunodermatology to help meet the needs of the millions of patients living with immune-mediated skin diseases.
Prior to Janssen, Lloyd served as Vice Chair for Research in Dermatology within the Department of Dermatology at Johns Hopkins. He was also a Professor of Dermatology, Infectious Diseases, Orthopedic Surgery and Materials Science and Engineering at the Johns Hopkins University School of Medicine.
A known leader in dermatology, Lloyd has published more than 100 peer-reviewed manuscripts, review articles, book chapters and editorials and has given more than 75 oral presentations at national and international scientific programs and meetings. Lloyd has received several grants from the National Institutes of Health (NIH), in addition to private foundation and industry funding for his research.
Lloyd received his M.D. and Ph.D. from the State University of New York Downstate Medical Center in Brooklyn, New York. He completed his dermatology residency and post-doctoral research fellowship in the Specialty Training and Advanced Research program at the University of California, Los Angeles.
Follow Lloyd on LinkedIn here.
Lloyd S. Miller, M.D., Ph.D.
Immunodermatology Disease Area Leader
TERENCE ROONEY, M.D.
IMMUNOLOGY DISEASE AREA LEADER
Terence Rooney, M.D., is Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in the rheumatology disease area, overseeing innovative compounds across multiple phases of development.
In his prior role at Janssen as Vice President, Immunology Clinical Development, Terence led the Late Development Clinical organization, overseeing all late-stage Immunology clinical trials. Under his leadership, the team delivered many important milestones, and evolved to meet the present and future needs of our growing and complex Immunology portfolio more sustainably. Prior to his time at Janssen, Terence held positions of increasing responsibility in translational/early and late clinical development at Roche and Eli Lilly, respectively.
Terence received his medical degrees from the Royal College of Surgeons in Ireland. During 10 years of academic clinical practice at teaching hospitals in Dublin, he completed postgraduate training in Rheumatology and Internal Medicine. His clinical/translational research fields of interest included rheumatoid arthritis biomarkers for the evolving targeted therapy era, in which he acquired a doctoral degree. He completed a post-fellowship attachment at the University of California San Francisco Division of Rheumatology before transitioning to work full time in pharmaceutical research and development. Terence is based at the Spring House, Pennsylvania campus, and lives with his family in Gladwyne, Pennsylvania.
Follow Terence on LinkedIn here.
Terence Rooney, M.D.
Immunology Disease Area Leader
JAN WEHKAMP, M.D.
GASTROENTEROLOGY DISEASE AREA LEADER
Jan Wehkamp, M.D. is Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in gastroenterology for many of Janssen’s active development programs including STELARA® (ustekinumab) and TREMFYA® (guselkumab), as well as many innovative compounds in early development.
Prior to his role at Janssen, Jan served as a Heisenberg Professor of Medicine, teaching innate immunology in inflammation and infection at the University of Tübingen in Baden-Württemberg, Germany. In addition, he was the Chief Scientific Officer for Defensin Therapeutics, a Danish biopharmaceutical company he cofounded in 2013, focused on developing and commercializing products for diseases associated with dysregulation of the human microbiota. Defensin Therapeutics’ research was based on more than two decades of expertise from Jan’s laboratory at the University of Tübingen.
Prior to this, Jan worked as a Principal Investigator of Research in Gastroenterology and Pharmacology at the Dr. Margarete-Fischer-Bosch-Institute of Clinical Pharmacology in Germany.
Jan has authored more than 120 publications and key presentations.
He received his M.D. from University of Lübeck in Germany and completed his post-doctoral work in immunology and microbiology at the Cleveland Clinic in Ohio and University of California in Davis, California.
Follow Jan on LinkedIn here.